Biotechnology News and Research

RSS

Calcivis announces completion of first clinical study of Caries Activity Imaging System

Calcivis, a medical devices company focused on revolutionising the management of tooth decay, today announces that it has completed a first clinical study of its Calcivis® Caries Activity Imaging System.

27 Nov 2014

ASBM announces results of European physician survey at EuropaBio – ASEBIO Meeting

The Alliance for Safe Biologic Medicines presented results from a survey of European physicians at the "1ST EuropaBio – ASEBIO Meeting on Innovation and Biological Therapies" at the Spanish Ministry of Health, Social Services and Equality.

27 Nov 2014

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.

27 Nov 2014

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital.

26 Nov 2014

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as electroCore’s non-invasive vagus nerve stimulation (nVNS).

26 Nov 2014

Research findings could lead to better tests for predicting breast cancer spread

A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.

26 Nov 2014

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

PharmaMar announces that Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS (trabectedin) to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

26 Nov 2014

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Surprisingly, even with decades of cryopreservation research, little progress has been made in the way frozen biospecimens are thawed. It’s still very common for researchers and clinicians to thaw cells and other frozen biological samples in a variety of manual ways ...

25 Nov 2014

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).

25 Nov 2014

New Mayo Clinic study shows impact of long-term use of proton pump inhibitors

Before reaching for that daily antacid, you might consider what it's doing to the trillions of bugs living in your gut. A new Mayo Clinic study in the open access journal Microbiome shows that people who regularly take proton pump inhibitors (PPIs) have less diversity among their gut bacteria, putting them at increased risk for infections like clostridium difficile and pneumonia, in addition to vitamin deficiencies and bone fractures.

25 Nov 2014

Flexure-based Electromagnetic Linear Actuator featured in 2014 R&D 100 Awards

A Flexure-Based Electromagnetic Linear Actuator (FELA) developed by the Singapore Institute of Manufacturing Technology, a research institute of the Agency for Science, Technology and Research, is the only locally-developed innovation featured in the 2014 R&D 100 Awards, an international competition that recognises the 100 most technologically-significant products introduced into the marketplace over the past year.

25 Nov 2014

Authors review current progress in developing transgenic pig models for human diseases

Genetically engineered pigs, minipigs, and microminipigs are valuable tools for biomedical research, as their lifespan, anatomy, physiology, genetic make-up, and disease mechanisms are more similar to humans than the rodent models typically used in drug discovery research.

24 Nov 2014

Researchers make significant breakthrough for sufferers of bone disease

Researchers in bone tissue regeneration believe they have made a significant breakthrough for sufferers of bone trauma, disease or defects such as osteoporosis.

24 Nov 2014

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults.

21 Nov 2014

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Scientists at the University of Texas Medical Branch were recognized with prestigious awards for their contributions in research at the annual American Society of Tropical Medicine and Hygiene meeting.

21 Nov 2014

Cocaine disrupts woman's estrus cycle, may explain sex differences in cocaine addiction

Women are more sensitive to the effects of cocaine and more susceptible to cocaine abuse than men. Cocaine's ability to disrupt a woman's estrus cycle may explain the sex differences in cocaine addiction, and new evidence that caffeine may be neuroprotective and able to block cocaine's direct effects on the estrus cycle reveals novel treatment possibilities, according to an article published in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

21 Nov 2014

People who handle complex jobs may have longer-lasting memory and thinking abilities

People whose jobs require more complex work with other people, such as social workers and lawyers, or with data, like architects or graphic designers, may end up having longer-lasting memory and thinking abilities compared to people who do less complex work, according to research published in the November 19, 2014, online issue of Neurology, the medical journal of the American Academy of Neurology.

20 Nov 2014

Leaders in research hope to uncover promising drugs in pharma libraries, conduct clinical trials

Drugs for brain diseases such as Alzheimer's, Parkinson's, and motor neurone disease that have stalled in development could be revived thanks to the efforts of a global coalition of non-profit organizations and funders announced today.

19 Nov 2014

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

The type 3 interferons - usually called the “lambda” interferons, or “IFNL” - are the most recently identified IFNs. We (myself and Sergei Kotenko) originally identified the receptor and then the three ligands (IFNL1,2,3; very recently a fourth, IFNL4, was discovered); the key paper was published in 2003.

18 Nov 2014

Biotechnology News and Research

Calcivis announces completion of first clinical study of Caries Activity Imaging System

ASBM announces results of European physician survey at EuropaBio – ASEBIO Meeting

Experimental Ebola vaccine appears safe, produces immune system responses in NIH phase 1 trial

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

Research findings could lead to better tests for predicting breast cancer spread

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

New Mayo Clinic study shows impact of long-term use of proton pump inhibitors

Flexure-based Electromagnetic Linear Actuator featured in 2014 R&D 100 Awards

Authors review current progress in developing transgenic pig models for human diseases

Researchers make significant breakthrough for sufferers of bone disease

2014 Canadian Prix Galien for Innovative Product Award presented to Esbriet (pirfenidone)

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Cocaine disrupts woman's estrus cycle, may explain sex differences in cocaine addiction

People who handle complex jobs may have longer-lasting memory and thinking abilities

Leaders in research hope to uncover promising drugs in pharma libraries, conduct clinical trials

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News